TLK286 (Telcyta) in Combination With Carboplatin (Paraplatin) Versus Doxil in Platinum Refractory or Resistant Ovarian Cancer
NCT00102973
Completed
The purpose of this research study is to determine if TLK286 given in combination with carboplatin is more effective than liposomal doxorubicin in treating women who have recurrent ovarian epithelial cancer, fallopian tube cancer, or primary peritoneal cancer, that is refractory or resistant to platinum chemotherapy.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
05/30/2012
Locations: Sinai Hospital of Baltimore, Baltimore, Maryland +1 locations
Conditions: Ovarian Neoplasms
Register for Updates
A Study of Cetuximab and Bevacizumab in Combination With Paclitaxel and Carboplatin in Stage IIIb/IV NSCLC
NCT00343291
Completed
The primary objective of this study will be to determine the progression free survival of patients with stage IIIb/IV non-small cell lung cancer (NSCLC) treated with dual agent monoclonal antibody therapy consisting of cetuximab and bevacizumab in combination with two different regimens of paclitaxel and carboplatin chemotherapy.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/13/2011
Locations: For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Baltimore, Maryland +1 locations
Conditions: Non-Small Cell Lung Cancer
Register for Updates
Fludeoxyglucose F18 Positron Emission Tomography Imaging In Assessing Patients Before and After Treatment for Locally Advanced Non-Small Cell Lung Cancer
NCT00083083
Unknown
RATIONALE: Imaging procedures, such as fludeoxyglucose F18 positron emission tomography (\^18FDG-PET), may improve the ability to detect disease progression and help doctors predict a patient's response to treatment and plan more effective treatment. PURPOSE: This phase II trial is studying how well \^18FDG-PET imaging works in detecting disease progression and determining response to treatment in patients who are undergoing chemoradiotherapy for locally advanced non-small cell lung cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/26/2011
Locations: Greenebaum Cancer Center at University of Maryland Medical Center, Baltimore, Maryland
Conditions: Lung Cancer
Register for Updates
Gemcitabine and Carboplatin Followed by Paclitaxel in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer
NCT00276588
Completed
RATIONALE: Drugs used in chemotherapy, such as gemcitabine, carboplatin, and paclitaxel work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more tumor cells. PURPOSE: This phase II trial is studying how well giving gemcitabine together with carboplatin followed by paclitaxel works in treating patients with stage III or stage IV non-small cell lung cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/05/2010
Locations: Greenebaum Cancer Center at University of Maryland Medical Center, Baltimore, Maryland +1 locations
Conditions: Lung Cancer
Register for Updates
Trial of Carboplatin/Paclitaxel/Cetuximab in Stage IIIB/IV Non-Small Cell Lung Cancer (NSCLC)
NCT00097227
Completed
The purpose of the study is to determine if the combination of cetuximab, carboplatin and paclitaxel will shrink a specific type of lung cancer known as non-small cell lung cancer (NSCLC). The safety of this combination will also be evaluated.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/08/2010
Locations: ImClone Investigational Site, Baltimore, Maryland
Conditions: Non-small Cell Lung Cancer
Register for Updates
Randomized Ph 2 Trial Of Paclitaxel/Carboplatin /Bevacizumab + PF-3512676 And P/C/B Alone In Advanced Nonsquamous NSCLC
NCT00313768
Terminated
To assess the efficacy and safety of PF-3512676 administered in combination with paclitaxel, carboplatin and bevacizumab as first-line treatment in patients with locally advanced or metastatic nonsquamous non-small cell lung cancer
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/24/2009
Locations: Pfizer Investigational Site, Baltimore, Maryland
Conditions: Carcinoma, Non-Small-Cell Lung
Register for Updates
STA-4783 in Combination With Paclitaxel and Carboplatin for the Treatment of Chemotherapy Naive Patients With Stage IIIB/IV Non Small Cell Lung Cancer (NSCLC)
NCT00088088
Completed
This study is for patients who have Stage IIIb or Stage IV NSCLC and have never had chemotherapy before for their disease. The first phase of the study recently completed and for the second phase of the study patients are randomly assigned to receive either paclitaxel and carboplatin or paclitaxel and carboplatin and study drug (STA 4783). Treatment will be every 3 weeks for 6 cycles.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/03/2008
Locations: Maryland Hematology and Oncology Associates, Baltimore, Maryland
Conditions: Stage IIIB Non-Small Cell Lung Cancer, Stage IV Non-Small Cell Lung Cancer
Register for Updates
Paclitaxel With or Without Carboplatin in Treating Women With Metastatic Breast Cancer
NCT00025688
Unknown
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known if paclitaxel is more effective with or without carboplatin in treating stage IV breast cancer. PURPOSE: Randomized phase III trial to compare the effectiveness of paclitaxel with or without carboplatin in treating women who have stage IV breast cancer.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
07/23/2008
Locations: Maryland Hematology/Oncology Associates, Baltimore, Maryland
Conditions: Breast Cancer
Register for Updates
A Phase 2 Trial of Antisense Nucleotide to PKC-Alpha (LY900003, ISIS 3521) Plus Gemcitabine and Carboplatin in Patients With Advanced, Previously Untreated Non-Small Cell Lung Cancer.
NCT00042679
Completed
The purposes of this study are to determine the following: Whether LY900003 plus gemcitabine and carboplatin can make your tumor smaller or disappear, and for how long. If treatment with LY900003 plus gemcitabine and carboplatin can help you live longer. The safety of LY900003 plus gemcitabine and carboplatin and any side effects that might be associated with the combination of these three drugs. How LY900003 is distributed and broken down by your body when it is given with carboplatin and g... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/18/2006
Locations: Not set, Baltimore, Maryland
Conditions: Carcinoma, Non-Small-Cell Lung, Pulmonary Neoplasms, Neoplasms, Lung
Register for Updates